The EVOLVE study is negative, so what does this 'bitter pill' of disappointment mean now for renal patients?

Area of Science:

• Nephrology
• Cardiology
• Public Health

Background:

• Chronic kidney disease (CKD) is associated with substantial morbidity and mortality.
• Cardiovascular disease (CVD) presents a significant burden in CKD patients, worsening as kidney function declines.
• Outcomes for patients starting renal replacement therapy are comparable to those with advanced solid organ malignancies.

Purpose of the Study:

• To underscore the persistent challenge of cardiovascular disease in chronic kidney disease.
• To highlight the severity of health outcomes in advanced CKD.
• To emphasize the need for continued vigilance and improved management strategies for CKD patients.

Main Methods:

• Review of existing literature on CKD, cardiovascular disease, and renal replacement therapy outcomes.
• Analysis of morbidity and mortality data in CKD populations.
• Examination of the impact of declining glomerular filtration rate (GFR) and increasing proteinuria on cardiovascular risk.

Main Results:

• Familiarity with CKD complications should not lead to underestimation of its severity.
• Cardiovascular disease risk and treatment challenges escalate with CKD progression.
• Renal replacement therapy initiation is associated with prognoses as poor as those for major cancers.

Conclusions:

• The burden of premature cardiovascular disease in CKD remains a critical issue.
• Significant or progressive CKD continues to pose a grave prognosis for patients, their families, and healthcare providers.
• Despite some progress, CKD necessitates ongoing attention and advanced management approaches to mitigate severe health outcomes.